The first observational reports on a cytoreductive effect of interferon α (IFNα) in CML patients date back to 1980s, when IFNα treatment was introduced at the M.D. Anderson Cancer Center, Houston, Texas [3, 4]. Here, IFNA17 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.